{"id":"W2569092380","doi":"10.1016/j.jtho.2016.11.1643","title":"P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; Internal medicine; Nausea; Adverse effect; Refractory (planetary science); Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Randomized controlled trial; Gastroenterology; Clinical trial; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003995495,0.00154237,0.002820328,0.0004159188,0.0004410059,0.002305964,0.001273923,0.001496683,0.006220962],"category_scores_gemma":[0.002640251,0.0005615692,0.002351393,0.0007293941,0.0009054633,0.001869544,0.0005757564,0.005401674,0.00220524],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001276506,"about_ca_system_score_gemma":0.001913613,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001383928,"about_ca_topic_score_gemma":0.005442983,"domain_scores_codex":[0.9991263,0.0003655847,0.00006863115,0.0001246354,0.000136068,0.0001789443],"domain_scores_gemma":[0.9988463,0.000266104,0.0002778807,0.0000901749,0.0001438625,0.0003756568],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6050148,0.004392994,0.004359873,0.003548824,0.005845335,0.000209886,0.0002511811,0.002355477,0.01440437,0.001389495,0.04274097,0.3154868],"study_design_scores_gemma":[0.9032179,0.05675957,0.01098781,0.0003592079,0.003091444,0.0003402797,0.00009680967,0.001429445,0.001611463,0.001387524,0.02064251,0.00007602709],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8647231,0.0681801,0.002764308,0.01731871,0.003145642,0.004666517,0.01132924,0.001441186,0.0264312],"genre_scores_gemma":[0.9245462,0.02899103,0.004622532,0.01181974,0.001499388,0.00374053,0.01319853,0.0003369487,0.0112452],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006220962,"threshold_uncertainty_score":0.02113044,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03058263829566181,"score_gpt":0.507547969852704,"score_spread":0.4769653315570422,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}